Publications by authors named "Silke Ehrenforth"

Claim this Profile
O
Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
Johannes Oldenburg, Manuel Carcao, Steven R Lentz, Johnny Mahlangu, Maria Elisa Mancuso, Silke Ehrenforth

Haemophilia· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Sandrine Meunier, Jayanthi Alamelu, Silke Ehrenforth, Hideji Hanabusa, Faraizah Abdul Karim

Thromb Haemost· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Paul Giangrande, Tatiana Andreeva, Pratima Chowdary, Silke Ehrenforth, Hideji Hanabusa

Thromb Haemost· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.
Erich V de Paula, Kaan Kavakli, Johnny Mahlangu, Yasmin Ayob, Steven R Lentz, Silke Ehrenforth

J Thromb Haemost· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.
Alex Veldman, Maureane Hoffman, Silke Ehrenforth

Curr Med Chem· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The deletion polymorphism in the angiotensin-converting enzyme gene is a moderate risk factor for venous thromboembolism.
Mario von Depka, Andreas Czwalinna, Cornelia Wermes, Roswith Eisert, Inge Scharrer, Silke Ehrenforth

Thromb Haemost· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.
Wolfhart Kreuz, Carmen Escuriola Ettingshausen, Alex Zyschka, Johannes Oldenburg, Inmaculada Martinez Saguer, Silke Ehrenforth

Semin Thromb Hemost· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis